top partner

for CFD

A disappointing quarter combined with a set of analyst price target cuts — and even a recommendation downgrade — made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of mid-afternoon Friday, according to data compiled by S&P Global Market Intelligence, the healthcare company’s share price had fallen by a steep 56% week to date.

Coherus had a bad third quarter

On Monday after market close, Coherus unveiled a set of third-quarter results that, despite a double-digit revenue increase, missed analyst estimates. It also cut full-year guidance for critical line items such as product revenue and research and development. Investors weren’t willing to look on the bright side (at that top-line improvement, for one thing), and they aggressively sold out of the stock.

As if that weren’t damaging enough, analysts were quick to get notably more bearish on the company’s prospects.

On Tuesday, H.C. Wainwright’s Jason Kolbert and Truist Securities’ Robyn Karnauskas both reduced their price targets on the biotech stock. Kolbert cut his level to $13 per share from the previous $20. He maintained his buy recommendation, however. Karnauskas made a nearly identical move, trimming her price target to $12 per share from $20. She also kept her buy designation intact.

The following day, another analyst went a step further by downgrading his recommendation on Coherus. Jason McCarthy of Maxim Group now feels the stock is only a hold, where formerly he had it tagged as a buy.

Analysts shouldn’t have the final say

We should never base our opinion of a stock on the moves of an analyst. Also, it’s easy to be bearish on a company after it reports a weak quarter. Not all aspects of Coherus’s latest quarter were worrying, although there was enough there to warrant concern about its current trajectory. Investors should always balance outside takes on a stock with their personal judgement, and act accordingly.

10 stocks we like better than Coherus BioSciences
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and Coherus BioSciences wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 6, 2023

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Truist Financial. The Motley Fool has a disclosure policy.

Read the full story: Read More“>

Blog powered by G6

Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.

For any inquiries, please contact [email protected]